Pancreatic Acinar Cell Carcinoma: Demographics, Treatment, and Survival Outcomes, A Retrospective Population-Based Study.

IF 1.6 Q4 ONCOLOGY

Journal of Gastrointestinal Cancer Pub Date : 2025-04-23 DOI:10.1007/s12029-025-01233-9

Abdul Qahar Khan Yasinzai, Asif Iqbal, Diego Olavarria-Bernal, Kalyani Ballur, Agha Wali, Shalini Ballur, Bisma Tareen, Marjan Khan, Hritvik Jain, Israr Khan, Nooran Fadhil, Amir Humza Sohail, Asad Ullah

{"title":"Pancreatic Acinar Cell Carcinoma: Demographics, Treatment, and Survival Outcomes, A Retrospective Population-Based Study.","authors":"Abdul Qahar Khan Yasinzai, Asif Iqbal, Diego Olavarria-Bernal, Kalyani Ballur, Agha Wali, Shalini Ballur, Bisma Tareen, Marjan Khan, Hritvik Jain, Israr Khan, Nooran Fadhil, Amir Humza Sohail, Asad Ullah","doi":"10.1007/s12029-025-01233-9","DOIUrl":null,"url":null,"abstract":"Purpose: Pancreatic acinar cell carcinoma accounts for 1-2% of pancreatic tumors, with increasing frequency in recent years, and still represents a poor prognosis. This study aims to expand and update existing literature by analyzing national data gathered over almost two decades.Methods: Data from 488 patients diagnosed with PACC in the Surveillance, Epidemiology, and End Results database were analyzed. This study employed the Cox regression method to compute hazard ratios and identify independent factors influencing survival. Additionally, Kaplan-Meier survival curves were utilized alongside the log-rank test.Results: The median age was 64.7 years with male predilection (70.5%). \"Poorly differentiated carcinoma\" was the most common subtype (45.8%). The liver was the most common site of metastases (31.3%). The 5-year observed overall survival (OS) rate was 19.2% (95% CI, 14.9-23.8). The 5-year cause-specific survival (CSS) rate was 22.4% (95% CI, 17.7-27.5). Male gender has a 5-year OS of 19.2% (95% CI, 14.0-25.1) compared to female OS of 30.2% (95% CI, 20.7-40.1). Patients treated with multimodal therapy (surgery with chemoradiation) over only surgery or chemotherapy had better 5-year OS, 53.5% (95% CI, 31.8-71.0). Age > 60 and distant stage were independent factors associated with increased mortality.Conclusion: Pancreatic acinar cell carcinoma is a rare, aggressive form of pancreatic cancer that primarily affects older adults. Our findings offer valuable insights to guide future clinical guidelines and tailored treatment strategies.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"106"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01233-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Pancreatic acinar cell carcinoma accounts for 1-2% of pancreatic tumors, with increasing frequency in recent years, and still represents a poor prognosis. This study aims to expand and update existing literature by analyzing national data gathered over almost two decades.

Methods: Data from 488 patients diagnosed with PACC in the Surveillance, Epidemiology, and End Results database were analyzed. This study employed the Cox regression method to compute hazard ratios and identify independent factors influencing survival. Additionally, Kaplan-Meier survival curves were utilized alongside the log-rank test.

Results: The median age was 64.7 years with male predilection (70.5%). "Poorly differentiated carcinoma" was the most common subtype (45.8%). The liver was the most common site of metastases (31.3%). The 5-year observed overall survival (OS) rate was 19.2% (95% CI, 14.9-23.8). The 5-year cause-specific survival (CSS) rate was 22.4% (95% CI, 17.7-27.5). Male gender has a 5-year OS of 19.2% (95% CI, 14.0-25.1) compared to female OS of 30.2% (95% CI, 20.7-40.1). Patients treated with multimodal therapy (surgery with chemoradiation) over only surgery or chemotherapy had better 5-year OS, 53.5% (95% CI, 31.8-71.0). Age > 60 and distant stage were independent factors associated with increased mortality.

Conclusion: Pancreatic acinar cell carcinoma is a rare, aggressive form of pancreatic cancer that primarily affects older adults. Our findings offer valuable insights to guide future clinical guidelines and tailored treatment strategies.

查看原文本刊更多论文

胰腺腺泡细胞癌：人口统计学、治疗和生存结果，一项基于人群的回顾性研究。

目的：胰腺腺泡细胞癌占胰腺肿瘤的1-2%，近年来发病率有所上升，但预后仍较差。本研究旨在通过分析近二十年来收集的国家数据来扩展和更新现有文献。方法：对监测、流行病学和最终结果数据库中488例确诊为PACC的患者的数据进行分析。本研究采用Cox回归方法计算风险比，确定影响生存率的独立因素。此外，Kaplan-Meier生存曲线与log-rank检验一起使用。结果：中位年龄64.7岁，男性优先（70.5%）。低分化癌是最常见的亚型（45.8%）。肝脏是最常见的转移部位（31.3%）。5年观察总生存率（OS）为19.2% （95% CI, 14.9-23.8）。5年病因特异性生存率（CSS）为22.4% （95% CI, 17.7-27.5）。男性的5年OS为19.2% (95% CI, 14.0-25.1)，而女性的5年OS为30.2% （95% CI, 20.7-40.1）。接受多模式治疗（手术加放化疗）的患者比仅接受手术或化疗的患者有更好的5年OS，为53.5% （95% CI, 31.8-71.0）。60岁以下和晚期是死亡率增加的独立因素。结论：胰腺腺泡细胞癌是一种罕见的侵袭性胰腺癌，主要影响老年人。我们的发现为指导未来的临床指南和量身定制的治疗策略提供了有价值的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gastrointestinal Cancer ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

121

期刊介绍： The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.